Australia's largest stock trading and investment forum Australia's #1 stock forum

CHM

Click for more information

0.00%

1.4¢ chimeric therapeutics limited

Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation, page-13

First 13 Last

Share
Profile

Follow
KrushingIt

96 Posts.

37

21/05/24

22:38

Post #: 73943269
Share

Originally posted by pinch2020: ↑

This is Hashan De Silva, runs KP Rx Healthcare Opportunities Fund. They haven't been around long but bought NEU at $1 and sold at $20.

Talks about how this is the best time ever to buy into the biotech market. He mentions companies who listed back in 2021 have been decimated by capital markets, some companies down 90% from their IPO struggling to now raise capital. Sound familiar? Listen to the very end of the video, "one company in particular we think we'll be able to enter at a $20million evaluation that is 3 years and a phase 2b trial away from a multi billion dollar exit". I wonder if that could be Chimeric and CHM 2101?

Expand

good find. Certainly sounds like CHM to me. He also talks about cellular therapy / immuneoncology….so I reckon it’s a distinct possibility that he is talking about CHM

CHM Price at posting: 2.3¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

A1G

African Gold finds significant 5.5g/t intercept over 65m in Cote d’Ivoire

Wealth Within: the latest stock tips from Dale Gillham

ASM

ASM to push Dubbo REE play towards economical production with A$5M Federal govt grant

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 6 more messages in this thread...

First 13 Last

Add CHM (ASX) to my watchlist

SPONSORED BY